[go: up one dir, main page]

DK1624868T3 - (2-Hydroxy-2(4-hydroxy-3-hydroxymethylphenyl)ethylamino)-propyl]phenyl-derivater som beta-2-agonister - Google Patents

(2-Hydroxy-2(4-hydroxy-3-hydroxymethylphenyl)ethylamino)-propyl]phenyl-derivater som beta-2-agonister

Info

Publication number
DK1624868T3
DK1624868T3 DK04730338T DK04730338T DK1624868T3 DK 1624868 T3 DK1624868 T3 DK 1624868T3 DK 04730338 T DK04730338 T DK 04730338T DK 04730338 T DK04730338 T DK 04730338T DK 1624868 T3 DK1624868 T3 DK 1624868T3
Authority
DK
Denmark
Prior art keywords
hydroxy
hydroxymethylphenyl
ethylamino
agonists
beta
Prior art date
Application number
DK04730338T
Other languages
English (en)
Inventor
Mark Edward Bunnage
Paul Alan Glossop
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1624868T3 publication Critical patent/DK1624868T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/14Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46Y being a hydrogen or a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DK04730338T 2003-05-15 2004-04-29 (2-Hydroxy-2(4-hydroxy-3-hydroxymethylphenyl)ethylamino)-propyl]phenyl-derivater som beta-2-agonister DK1624868T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03010944A EP1477167A1 (en) 2003-05-15 2003-05-15 [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GBGB0329874.2A GB0329874D0 (en) 2003-05-15 2003-12-23 Compounds useful for the treatment of diseases
PCT/IB2004/001519 WO2004100950A1 (en) 2003-05-15 2004-04-29 ‘(2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)-propyl!phenyl derivatives as beta2 agonists

Publications (1)

Publication Number Publication Date
DK1624868T3 true DK1624868T3 (da) 2009-02-23

Family

ID=33454327

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04730338T DK1624868T3 (da) 2003-05-15 2004-04-29 (2-Hydroxy-2(4-hydroxy-3-hydroxymethylphenyl)ethylamino)-propyl]phenyl-derivater som beta-2-agonister

Country Status (29)

Country Link
EP (2) EP1477167A1 (da)
JP (1) JP3966897B2 (da)
KR (1) KR100749990B1 (da)
CN (1) CN1791407A (da)
AP (1) AP2005003443A0 (da)
AR (1) AR044335A1 (da)
AT (1) ATE413879T1 (da)
AU (1) AU2004237952A1 (da)
BR (1) BRPI0410391A (da)
CA (1) CA2525006A1 (da)
CL (1) CL2004000963A1 (da)
CO (1) CO5700776A2 (da)
DE (1) DE602004017710D1 (da)
DK (1) DK1624868T3 (da)
EA (1) EA200501615A1 (da)
EC (1) ECSP056164A (da)
ES (1) ES2314395T3 (da)
GB (1) GB0329874D0 (da)
IS (1) IS8080A (da)
MA (1) MA27840A1 (da)
MX (1) MXPA05012329A (da)
NL (1) NL1026203C2 (da)
NO (1) NO20055854L (da)
OA (1) OA13165A (da)
PA (1) PA8603001A1 (da)
PE (1) PE20060095A1 (da)
TW (1) TW200505865A (da)
UY (1) UY28317A1 (da)
WO (1) WO2004100950A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548318A (en) 2004-01-22 2009-03-31 Pfizer Sulfonamide derivatives for the treatment of diseases
EP1708992B1 (en) 2004-01-22 2007-08-08 Pfizer Limited Sulfonamide derivatives for the treatment of diseases
JP4054366B2 (ja) * 2004-03-17 2008-02-27 ファイザー・インク 疾患の治療のために有用な化合物
WO2005092860A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds for the treatment of diseases
EA200601462A1 (ru) * 2004-03-23 2007-04-27 Пфайзер Инк. Соединения для лечения заболеваний
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5629200A (en) * 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5561142A (en) * 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
MX9708621A (es) * 1995-05-10 1998-02-28 Pfizer AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS.
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist

Also Published As

Publication number Publication date
AR044335A1 (es) 2005-09-07
KR100749990B1 (ko) 2007-08-16
NL1026203C2 (nl) 2005-07-26
CO5700776A2 (es) 2006-11-30
CL2004000963A1 (es) 2005-03-18
NL1026203A1 (nl) 2004-11-16
NO20055854L (no) 2006-02-10
ECSP056164A (es) 2006-04-19
MA27840A1 (fr) 2006-04-03
PE20060095A1 (es) 2006-02-18
EA200501615A1 (ru) 2006-06-30
AP2005003443A0 (en) 2005-12-31
DE602004017710D1 (de) 2008-12-24
EP1624868B1 (en) 2008-11-12
UY28317A1 (es) 2004-12-31
JP2007503458A (ja) 2007-02-22
CA2525006A1 (en) 2004-11-25
JP3966897B2 (ja) 2007-08-29
KR20060017607A (ko) 2006-02-24
OA13165A (en) 2006-12-13
MXPA05012329A (es) 2006-01-30
TW200505865A (en) 2005-02-16
EP1477167A1 (en) 2004-11-17
ES2314395T3 (es) 2009-03-16
BRPI0410391A (pt) 2006-07-18
EP1624868A1 (en) 2006-02-15
PA8603001A1 (es) 2004-12-16
GB0329874D0 (en) 2004-01-28
AU2004237952A1 (en) 2004-11-25
CN1791407A (zh) 2006-06-21
EP1624868B9 (en) 2009-08-12
ATE413879T1 (de) 2008-11-15
WO2004100950A1 (en) 2004-11-25
IS8080A (is) 2005-10-20

Similar Documents

Publication Publication Date Title
DK1624868T3 (da) (2-Hydroxy-2(4-hydroxy-3-hydroxymethylphenyl)ethylamino)-propyl]phenyl-derivater som beta-2-agonister
DK2308419T3 (da) Fremgangsmåde til bedømmelse af farvningstilstandene for dyresperm, som skal sorteres.
DE602004007503D1 (de) REKONFIGURIERBARE ARCHITEKTUR FÜR SOCs
DK1699797T3 (da) Pyrrolotriazinforbindelser som kinasehæmmere
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1644397T3 (da) Specifik glucocorticosteroidforbindelse som har antiinflammatorisk aktivitet
NO20044174L (no) Kumariner som er nyttige som biomarkorer
NO20030929L (no) Guanidinobenzamider som MC4-R agonister
DK1912991T3 (da) Xanthinderivater som selektive HM74A-Agonister
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
IS8323A (is) Ný amínóbensófenónefnasambönd
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
NO20055166D0 (no) Acylerte spiropiperidinderivater som melanokortin-4-reseptoragonister
EP1849305A4 (en) HIDE DISORDER
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DK1705989T3 (da) Substituerede arylpyrazoler som parasiticide midler
DK1438289T3 (da) Indolderivater som cox II-inhibitorer
DE60303566D1 (de) Viterbi Dekodierer für gigabit Ethernet
NO20044092L (no) Oftalmisk sammensetning som innbefatter ascomycin
DK1511718T3 (da) N-acylaminobenzenderivater som selektive monoaminoxidase B-inhibitorer
DK1680425T3 (da) 6-[(substitueret)phenyl]triazolopyrimidiner som anticancermidler
NO20033234L (no) Karotenoider som antihypertensjonsmidler